• Traverse
    • Timmerman Traverse for Damon Runyon 2027
    • Past Climbs (2018-2026)
  • The Long Run Podcast
  • About
    • Speaking
    • Podcast
    • Events
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
Biotech Leaders Get It
  • Traverse
    • Timmerman Traverse for Damon Runyon 2027
    • Past Climbs (2018-2026)
  • The Long Run Podcast
  • About
    • Speaking
    • Podcast
    • Events
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
14
Nov
2024

RFK Jr. to HHS. I Was Wrong

/
Luke Timmerman
/
2
/
All
14 Nov 2024

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.

Subscribe Now
Sign in to your account.

You may also like

Merck Bets on KRAS Drug, Kodiak Hunts Down Regeneron, & Lycia Preps for IPO
08 Oct 2026
Enveda Cashes In, Otsuka Hits ALS Goal, & Viking Braces for GLP-1 Battle
24 Sep 2026
Scholar Rock Gets FDA OK, Reverse Mergers Continue & Novartis Bets on Brain Delivery
17 Sep 2026
Novartis’ Rough Week, AstraZeneca’s Better Week, & GV Life Sciences Leader Moves On
10 Sep 2026

Get In-depth Biotech Coverage with Timmerman Report.

Individual Subscription

Group Subscription

Or: Sign in to your account

Your account

Sign in

What Readers Are Saying

testimonial

View More Testimonials ➛

© Copyright 2026, TimmermanReport.com
Privacy Policy | Terms of Use
Custom WordPress site by: Perception Builder